Follicular lymphoma survivor Troy Anderson credited acupuncture and nutrition guidance with easing treatment side effects and ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

A local Omaha woman was the first to ever receive CAR T-cell therapy as an outpatient. Doctors said it was a success, and she ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

A man from Swindon will be taking part in a 38-mile cycle after successfully undergoing treatment for follicular lymphoma.

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Follicular lymphoma may be associated with the presence of abnormal immune system function and conditions such as HIV, rheumatoid arthritis, lupus, or celiac disease in which the immune system is ...

Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...

Background: Follicular lymphoma (FL) is an incurable disease in which patients will relapse despite the effectiveness of first-line (1L) rituximab-based chemoimmunotherapy (CIT), indicating the need ...